ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
메트포르민 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 연평균 7.1%의 CAGR로 58억 8,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 신흥 시장 확대, 메트포르민에 대한 인식 및 채택 증가, 인구 고령화, 특허 만료 및 제네릭 경쟁, 병용요법에 대한 수요 증가, 부작용에 대한 인식 증가, 안전성에 대한 우려 등에 기인하는 것으로 추정됩니다. 예측 기간 동안 주요 동향으로는 신제품 출시, 생활습관 개입, 연구 개발, 파트너십 증가, 제조 기술 발전 등을 들 수 있습니다.
당뇨병 유병률의 증가는 향후 몇 년 동안 메트포르민 시장의 성장을 크게 촉진할 것으로 예상됩니다. 당뇨병은 췌장에서 충분한 인슐린이 분비되지 않거나 분비된 인슐린을 신체가 효과적으로 사용할 수 없을 때 발생하며, 혈당 수치가 높아지는 질환입니다. 당뇨병의 유병률 증가 요인으로는 비만 유행, 유전적 소인, 건강에 해로운 생활습관 선택, 의료 서비스 접근성 제한, 특정 환경 독소에 대한 노출 등이 있습니다. 메트포르민은 혈당을 낮추고, 인슐린 감수성을 개선하며, 체중 감소를 돕고, 심혈관계에 이점을 줄 수 있기 때문에 제2형 당뇨병 관리에 중요한 역할을 합니다. 예를 들어, Diabetes Canada에 따르면 2023년 2월 캐나다의 당뇨병 환자 수는 2023년 240만 9,000명(인구의 15%)에서 2033년 300만 9,000명(인구의 17%)으로 증가할 것으로 예측됩니다. 당뇨병 유병률이 지속적으로 증가함에 따라 메트포르민에 대한 수요가 확대되어 메트포르민 시장 확대를 더욱 촉진할 것으로 예상됩니다.
메트포르민 시장의 주요 기업들은 시장 지위를 강화하기 위해 3제 복합제(FDC)와 같은 혁신적인 당뇨병 치료제 개발에 주력하고 있으며, 3제 복합제 FDC는 세 가지 다른 항당뇨병제를 하나의 정제 또는 캡슐에 혼합하여 제2형 당뇨병 환자의 혈당을 시너지 효과를 발휘하여 혈당 조절을 강화하는 것을 목표로 하고 있습니다. 혈당 조절을 강화하는 것을 목적으로 합니다. 예를 들어, 인도 글렌마크 파마슈티컬스는 2023년 10월 테네리글립틴과 다파글리플로진, 메트포르민을 결합한 인도 최초의 3제 복합 FDC인 Zita DM을 출시했습니다. 10mg), 메트포르민 SR(500mg/1000mg)을 고정 용량으로 함유하고 있으며, 성인 제2형 당뇨병 환자, 특히 메트포르민만으로 혈당 조절이 충분하지 않거나 추가 치료가 필요한 환자들의 혈당 조절을 개선하도록 설계됐습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신종 코로나바이러스 감염증, 그리고 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 메트포르민 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 메트포르민 시장 : 성장률 분석
세계의 메트포르민 시장 실적 : 규모와 성장, 2019-2024
세계의 메트포르민 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 메트포르민 전체 시장(TAM)
제6장 시장 세분화
세계의 메트포르민 시장 : 제품 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
표준 방출정
서방정
세계의 메트포르민 시장 : 투여량별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
500MG
750MG
850MG
1G
세계의 메트포르민 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
클리닉
병원
홈케어
기타 최종사용자
세계의 메트포르민 시장, 표준 방출정 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
500mg
850mg
1000mg
세계의 메트포르민 시장, 서방정 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
500mg
750mg
1000mg
제7장 지역별·국가별 분석
세계의 메트포르민 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 메트포르민 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
메트포르민 시장 : 경쟁 구도
메트포르민 시장 : 기업 개요
Wockhardt Limited Overview, Products and Services, Strategy and Financial Analysis
Aarti Drugs Overview, Products and Services, Strategy and Financial Analysis
Abhilash Chemicals Private Limited Overview, Products and Services, Strategy and Financial Analysis
Farmhispania Overview, Products and Services, Strategy and Financial Analysis
Rochem International Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Jai Radhe Sales
Chr. Olesen Group
Aspire Lifesciences Pvt. Ltd.
Ria Lifesciences Pvt. Ltd.
Shree Sadguru
LGM Pharma
HRV Global Life Sciences
Octavius Pharma Pvt. Ltd.
USV Private Limited
Zeon Pharma Industries India Pvt. Ltd.
Atman Pharmaceuticals
Aastrid International Pvt. Ltd.
Abhilasha Pharma
Anwita Drugs & Chemicals Pvt. Ltd.
IOL Chemicals and Pharmaceuticals
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
메트포르민 시장 2029 : 새로운 기회를 제공하는 국가
메트포르민 시장 2029 : 새로운 기회를 제공하는 부문
메트포르민 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Metformin is an oral medication primarily used for managing type 2 diabetes, classified under the biguanides class of drugs. Its mechanism involves reducing glucose production in the liver, enhancing insulin sensitivity to promote glucose uptake by muscles, and decreasing glucose absorption from the intestines.
The main formulations of metformin include standard-release tablets and slow-release tablets. Standard-release tablets release the active ingredient quickly after ingestion, facilitating rapid control of blood sugar levels. Metformin is available in various dosages such as 500mg, 750mg, 850mg, and 1g, catering to diverse end-users including clinics, hospitals, homecare settings, and other healthcare providers.
The metformin market research report is one of a series of new reports from The Business Research Company that provides metformin market statistics, including metformin industry global market size, regional shares, competitors with a metformin market share, detailed metformin market segments, market trends, and opportunities, and any further data you may need to thrive in the metformin industry. This metformin research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The metformin market size has grown strongly in recent years. It will grow from $4.17 billion in 2024 to $4.48 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rise in the prevalence of diabetes, growth in awareness of diabetes, and increasing healthcare spending.
The metformin market size is expected to see strong growth in the next few years. It will grow to $5.88 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to expansion in emerging markets, growing awareness, and adoption of metformin, aging Population, patent expiry and generic competition, increasing demand for combination therapies, increased awareness of side effects, and safety concerns. Major trends in the forecast period include the launch of new products, lifestyle interventions, research and development, increasing partnerships, and advancements in manufacturing technology.
The increasing prevalence of diabetes is expected to significantly propel the growth of the metformin market in the coming years. Diabetes occurs when the pancreas either does not produce enough insulin or when the body cannot effectively use the insulin it produces, leading to high blood sugar levels. Contributing factors to the rising prevalence of diabetes include the obesity epidemic, genetic predispositions, unhealthy lifestyle choices, limited access to healthcare, and exposure to certain environmental toxins. Metformin plays a crucial role in managing type 2 diabetes by lowering blood sugar levels, improving insulin sensitivity, supporting weight loss, and potentially offering cardiovascular benefits. For example, according to Diabetes Canada, in February 2023, the estimated number of diabetes cases in Canada was projected to increase from 2,409,000 (15% of the population) in 2023 to 3,009,000 (17% of the population) by 2033. As the prevalence of diabetes continues to rise, the demand for metformin is expected to grow, further driving the expansion of the metformin market.
Leading companies in the metformin market are focusing on developing innovative diabetes medications, such as triple-drug Fixed-Dose Combinations (FDC), to strengthen their market positions. A triple-drug FDC combines three different antidiabetic medications into a single tablet or capsule, aiming to synergistically manage blood sugar levels and enhance glycemic control in patients with type 2 diabetes. For instance, Glenmark Pharmaceuticals, an India-based company, launched Zita DM in October 2023, the first triple-drug FDC of teneligliptin with dapagliflozin and metformin in India. Zita DM contains teneligliptin (20 mg), dapagliflozin (10 mg), and metformin SR (500 mg/1000 mg) in a fixed dose, designed to improve glycemic control in adults with type 2 diabetes, especially those who do not achieve adequate control with metformin alone or require additional therapies.
In April 2023, SK Capital Partners LP, a US-based investment firm, acquired Apotex Pharmaceutical Holdings Inc. to expand its presence in the pharmaceutical industry. This acquisition positions SK Capital to leverage Apotex's extensive portfolio of generic medications, including metformin, strengthening its capabilities and market reach. Apotex Pharmaceutical Holdings Inc., headquartered in Canada, is recognized for its production of metformin and other essential pharmaceuticals.
Major companies operating in the metformin market are Wockhardt Limited, Aarti Drugs, Abhilash Chemicals Private Limited, Farmhispania, Rochem International Inc., Jai Radhe Sales, Chr. Olesen Group, Aspire Lifesciences Pvt. Ltd., Ria Lifesciences Pvt. Ltd., Shree Sadguru, LGM Pharma, HRV Global Life Sciences, Octavius Pharma Pvt. Ltd., USV Private Limited, Zeon Pharma Industries India Pvt. Ltd., Atman Pharmaceuticals, Aastrid International Pvt. Ltd., Abhilasha Pharma, Anwita Drugs & Chemicals Pvt. Ltd., IOL Chemicals and Pharmaceuticals, Gangwal Healthcare, Granules India Limited, Alekhya Drugs Pvt. Ltd, Angels Pharma India Private Limited, Auro Laboratories Ltd.
North America was the largest region in the metformin market in 2024. The regions covered in the metformin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the metformin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The metformin market consists of sales of glucophage, fortamet, glumetza, riomet, and linagliptin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Metformin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on metformin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for metformin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metformin market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Standard-Release Tablets; Slow-Release Tablets
2) By Dosage Type: 500MG; 750MG; 850MG; 1G
3) By End-user: Clinics; Hospitals; Homecare; Other End-Users
Subsegments:
1) By Standard-Release Tablets: 500 Mg; 850 Mg; 1000 Mg
2) By Slow-Release Tablets: 500 Mg; 750 Mg; 1000 Mg
Companies Mentioned: Wockhardt Limited; Aarti Drugs; Abhilash Chemicals Private Limited; Farmhispania; Rochem International Inc.
